Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. RedHill Biopharma Ltd.’s current trading price is -97.85% away from its 52-week high, while its distance from the 52-week low is 4.33%. The stock’s price range during this period has varied between $0.79 and $38.40. The company, active in the Healthcare sector, saw a trading volume of around 9.25 million for the day, considerably higher average daily volume of 0.22 million observed over the last three months.
Currently, the stock price of RedHill Biopharma Ltd. (RDHL) is $0.82. In the most recent trading session, the stock underwent a significant upswing, peaking at $0.8597 after opening at $0.84. The stock touched a low of $0.80 before closing at $0.85.
RedHill Biopharma Ltd.’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $38.40 on 10/19/22, and the lowest price during that time was $0.79, recorded on 09/18/23.
How Financial Performance Impacts Market Capitalization
RedHill Biopharma Ltd. (RDHL) has experienced a quarterly decline of -58.58% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.75M and boasts a workforce of 113 employees.
Decoding Analysts’ Ratings for RedHill Biopharma Ltd.
As of right now, 1 analyst is rating RedHill Biopharma Ltd. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.5340, with a change in price of -1.6369. Similarly, RedHill Biopharma Ltd. recorded 261,939 in trading volume during the last 100 days, posting a change of -66.54%.
How RDHL’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RDHL stands at 0.66. Similarly, the long-term debt-to-equity ratio is also 0.29.
RDHL Stock Stochastic Average
As of today, the raw stochastic average of RedHill Biopharma Ltd. over the past 50 days is 2.87%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 15.20%. Additionally, the Stochastic %K and %D values for the company were 20.05% and 18.58%, respectively, over the past 20 days.
RDHL Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price decrease of -85.31%. However, over the past six months, we’ve seen a stronger performance of -84.88%. The price of RDHL leaped by -11.38% over the last 30 days. And in the last five days, it has fallen by -1.83%.